First lady Melania Trump took a swipe at Democratic lawmakers for their low attendance at a roundtable on deepfakes and ...
Many Marylanders struggle with obesity but cannot get access to weight loss medications because insurance will not pay for ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...
Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of ...
Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results